| Identification | Back Directory | [Name]
LORCASERIN | [CAS]
616202-92-7 | [Synonyms]
Apd356
Ar-10a
Apd 356
Apd-356
LORCASERIN
Unii-637E494o0z
Lotcaserin Freebase
(R)-8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
(1R)-8-Chloro-2,3,4,5-tetrahydro-1-Methyl-1H-3-benzazepine | [EINECS(EC#)]
809-254-4 | [Molecular Formula]
C11H14ClN | [MDL Number]
MFCD09833670 | [MOL File]
616202-92-7.mol | [Molecular Weight]
195.692 |
| Chemical Properties | Back Directory | [Boiling point ]
288 ºC | [density ]
1.075 | [Fp ]
128 ºC | [storage temp. ]
-20?C Freezer | [solubility ]
Chloroform (Slightly), Methanol (Slightly) | [form ]
Light Beige to Beige Semi-Solid | [pka]
9.99±0.40(Predicted) | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Chemical Properties]
Yellow Oil | [Definition]
ChEBI: A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine substituted at position 1 by a methyl group and a t position 6 by a chloro group. | [Mechanism of action]
Lorcaserin acts at 5-HT2C receptors in the central nervous system (CNS), particularly the hypothalamus, to reduce appetite. | [Side effects]
- constipation
- dry mouth
- excessive tiredness
- pain in the back or muscles
- headache
- dizziness
- difficulty falling asleep or staying asleep
- anxiety
| [Synthesis]
The synthesis of LORCASERIN is as follows:
Liquid precursor 53 11-HCl (0.5mmol) was placed into a test tube equipped with a magnetic stir bar. Anhydrous 44 AlCl3 (1.75 equiv according to starting material) was added and efficiently mixed to obtain a paste. The mixture was slowly heated (10°C/min) to 150°C and stirred overnight. A saturated solution of 54 NaCl was added and the mixture was cooled. The pH was adjusted to 9.5-10 using 1M NaOH and then extracted with EtOAc. The combined organic phases were washed with brine, dried over Na2SO4 and the solvent was evaporated under reduced pressure. The obtained crude mixture was analyzed using 1H NMR spectroscopy (estimated yield by 1H NMR was 62%).
 |
| Questions And Answer | Back Directory | [Weight loss drugs]
Lorcaserin is a new drug for the treatment of obesity , belonging to oral potent selective serotonin 2C receptor agonists, lorcaserin hydrochloride is successfully developed by the US company Arena, on June 27, 2012 by the US FDA it is approved for marketing, as adjuvant therapy for obesity or merge with at least one weight-related complications in overweight adults in low-calorie diet and exercise basis . Clinical studies show that the drug can reduce weight of obesity and overweight patients ,it can improve obesity-related metabolic parameters, and it is well tolerated. Lorcaserin affinity for the 5-HT2c 100 times higher than the 5-HT2B (valvular heart disease risk) ,it has good safety,it is the first FDA-approved weight-loss drug after 1999 . In a year of Lorcaserin treatment, the average weight loss ranges from 3 to 3.7 percent.
| [Drug Interactions]
Due to the theoretical possibility of the mechanism of lorcaserin and serotonin syndrome, when lorcaserin is used in combination with the serotonergic neurotransmitter system drugs, extreme caution should be paid, including triptans monoamine oxidase inhibitor agent selective serotonin reuptake inhibitor selective serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants bupropion dextromethorphan, lithium tramadol and St. John's wort , etc. In addition, when the present product with CYP2D6 substrates when combined with the need to be cautious, because the product can increase the exposure of these drugs.
The above information is edited by the Chemicalbook of Tian Ye.
| [safety ]
Lorcaserin has good tolerability and safety, lorcaserin is used in non-diabetic patients, the most common adverse reactions are headache, dizziness, fatigue, nausea, dry mouth and constipation. This product is used in patients with diabetes, common adverse reactions are headache, back pain, cough, low blood sugar and fatigue.studies have found that lorcaserin and placebo are Similar in the proportion of serious adverse reactions, lorcaserin does not increase the incidence of valvular heart disease. After lorcaserin treatment , the incidence of depression is lower , the research shows that the proportion of depression led by lorcaserin 10mgbid, 10mgqd and placebo are 1.9%, 1.1% and 1.8%, emotional low incidence rates are 0.6%, 0.9% and 0.9%, the proportion of suicidal thoughts are 0.9%, 0.6% and 0.7% .the product is pregnancy X-class , pregnant women are disabled; whether this product is secreted by milk is unknown, breast-feeding women need to weigh on the use of the drug; this product is not recommended for children.
| [Uses]
diet pills. Lorcaserin was used to treat Opioid Use Disorder (OUD).
|
|